🇺🇸 FDA

Company profile · Sponsor

Edesa

Edesa Biotech

EDSA · NYSE biotech MARKHAM, USA
Pipeline
5
Drugs
0
Patents
0

Quick answer

Edesa (EDSA) is a biotech company. headquartered in MARKHAM, USA. listed on NYSE. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EDSA
Exchange NYSE
Company type biotech
Headquarters MARKHAM, USA
SEC CIK 0001540159

Pipeline (5)

Search pipeline →

  1. SOC plus 15mg/kg EB05 IV

    Edesa

    COVID-19

    phase 3 mab on hold

    1 trial

  2. Cohort A: vilobelimab

    Edesa

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    2 trials

  3. Cohort B: paridiprubart

    Edesa

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  4. Cohort C: bevacizumab

    Edesa

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  5. EB01 Cream Placebo

    Edesa

    Allergic Contact Dermatitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is Edesa?

Edesa (EDSA) is a biotech company. headquartered in MARKHAM, USA. listed on NYSE. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Edesa sponsor?

We track 5 ClinicalTrials.gov-linked programs for Edesa, including SOC plus 15mg/kg EB05 IV and 4 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Edesa company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.